Ovarian Cancer Clinical Trial Results Published
A study evaluated the effectiveness of combined drug regimens for treating recurrent epithelial ovarian cancer.
Updated on Oct. 13, 2026 in Cancer
Researchers have published results from a phase II clinical trial investigating the efficacy of durvalumab, olaparib, and cediranib in patients with recurrent epithelial ovarian cancer. The study enrolled 68 participants to assess response rates and progression-free survival across different treatment combinations.
Why it matters
Evaluating novel drug combinations is crucial for identifying potential treatments for recurrent ovarian cancer, where therapeutic options often remain limited. Understanding how these therapies perform helps clinicians determine the viability of multi-drug regimens for patients facing recurrent disease.
The study involved 68 patients, with 39 receiving a three-drug regimen and 29 receiving a two-drug regimen. Both arms reported a median progression-free survival of 4.5 months.
The players
Durvalumab
This is a checkpoint inhibitor medication used in cancer immunotherapy.
Olaparib
This is a PARP inhibitor medication often utilized to target cancer cells with DNA repair deficiencies.
Cediranib
This is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.
The details
Researchers performed whole exome sequencing on pre-treatment biopsies and peripheral blood mononuclear cells to compare genomic profiles against clinical outcomes. While most cases across both study arms presented with TP53 mutations, genomic markers did not clearly predict which patients would show the greatest clinical benefit.
Timeline
October 13, 2026: Study results were officially published.
The Big Picture
This study aligns with established research frameworks at the National Center for Biotechnology Information (NCBI) database. It contributes to the broader oncology field by providing structured data on the performance of complex immunotherapy and targeted therapy combinations.
The results suggest that while these drug combinations offer some clinical activity, they do not provide a universal improvement in outcomes for all recurrent ovarian cancer patients. Patients and providers should discuss these findings when considering enrollment in future clinical trials or weighing existing treatment pathways.
The takeaway
Clinical trial data helps identify which patients may benefit from experimental multi-drug therapies through rigorous testing and genomic analysis. Healthcare providers can use these findings to better navigate treatment strategies for patients with recurring ovarian cancer.
Further reading
For more information on current treatment developments, visit the Cancer section.
More information
View the full details on the NCBI clinical trial data page.
